Biomarin Pharmaceutical Inc to Discuss Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update Call Transcript
Welcome to the BioMarin valrox Phase II/Phase III Update Call. (Operator Instructions) And today's call is being recorded.
It is now my pleasure to turn today's program over to Ms. Traci McCarty. Please go ahead.
Thank you, operator, and thank you all for joining us this morning to discuss the Phase II and Phase III data update with valoctocogene roxaparvovec or valrox for the treatment of severe hemophilia A. Today's press releases are available on the Investor page of our website and today's slide presentation will be posted at the end of this call. For viewing the slides being presented during the call now, you can access them via the webcast link on the press release.
On the call today from BioMarin management are J.J. Bienaimé, our Chairman and CEO; and Dr. Hank Fuchs, BioMarin's President Worldwide Research and Development; and joining during the Q&A portion of today's call is Dan Spiegelman, Executive Vice President and CFO; and Robert Baffi, Executive Vice President,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |